Lupin Must Halt Sales Of Generic Diabetes Drug: Judge

Law360, New York (December 6, 2011, 9:49 PM EST) -- A federal judge on Tuesday ordered Lupin Ltd. to stop selling its generic version of Type 2 diabetes treatment Fortamet, the subject of a patent infringement suit, but denied patent holder Shionogi Pharma Inc.'s request to recall the generics already on the market.

U.S. District Judge Robert B. Kugler granted Shionogi's preliminary injunction request on the grounds that it post a $15 million security bond payable to Lupin if the generic-drug maker prevails in the patent infringement suit, which is expected to be completed in about...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.